|Bid||14.85 x 900|
|Ask||16.48 x 1100|
|Day's Range||15.52 - 16.31|
|52 Week Range||12.32 - 25.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018-- Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial ...
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 clinical study with DNL201, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). In a randomized, double blind, placebo-controlled, oral dose study in healthy subjects, DNL201 achieved its safety, pharmacokinetic, and pharmacodynamic objectives.
Alector is developing drugs that target the immune system in the brain, much like cancer immunotherapy drugs have shown success in boosting the body's immune system against tumors.
Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has exercised its option to acquire all outstanding shares in F-star Gamma pursuant to the Option Agreement dated August 24, 2016 and expanded its collaboration with F-star on Denali’s biologics Transport Vehicle (“TV”) blood-brain barrier (“BBB”) platform technology. Denali entered into a License and Collaboration Agreement with F-star in August 2016 to support the development of and provide rights to intellectual property for Denali’s proprietary TV platform technology to deliver therapeutics across the BBB.
Five years after the company started and two years after it moved into the new biotech lab-office project at Highway 101 and Oyster Point Boulevard, this company with experimental drugs in Alzheimer's, Parkinson's and ALS will quadruple its space.
Denali Therapeutics (DNLI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Takeda Pharmaceutical Company Limited and Denali Therapeutics today announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.
A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI ), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. ...
Denali Therapeutics Inc. (NASDAQ: DNLI ), a biotech company focusing on therapies for neurodegenerative disorders, IPO-ed in Dec. 2017, offering 13.9 million shares at $18 each. The Analyst Goldman Sachs ...
Menlo Therapeutics Inc. filed Thursday to raise up to about $98 million in what could be the first IPO of the New Year from the Bay Area. South San Francisco-based Denali Therapeutics Inc. (DNLI) raised $229 million earlier this month and San Jose-based Restoration Robotics (HAIR) raised $25 million in mid-October. Menlo Therapeutics started out in 2011 under the name Tigercat Pharma Inc. and changed its name to Menlo Therapeutics in May 2016. It has raised about $110 million in funding, including a July round of $50 million this year that gave it a valuation of about $210 million, according to PitchBook Data.
Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.